ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.